Marinomed Signs Drug Discovery Collaboration with BIOALVO
Under the terms of the deal BIOALVO will grant Marinomed access to BIOALVO’s PharmaBUG natural marine extracts. Marinomed will then have exclusive rights to use its own screening platform to identify those with therapeutic potential for indications in the areas of immunology and infectious diseases.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “We are delighted to have signed this collaboration with BIOALVO. The rich source of natural marine extracts from PharmaBUG offers us a unique resource to screen and hopefully generate new natural leads for development in our core therapeutic indications.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.